New HIV vaccine candidates pass early safety check in human trial

NCT ID NCT03220724

First seen Apr 02, 2026 · Last updated Apr 29, 2026 · Updated 5 times

Summary

This early-stage study tested two experimental HIV vaccines in 117 healthy, HIV-negative adults to see if they are safe and can trigger an immune response. Participants received several shots of the vaccines, which were designed to train the body to recognize HIV. The main goal was to check for side effects and measure antibody production, helping researchers decide whether to move forward with larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alabama CRS

    Birmingham, Alabama, 35294, United States

  • Bridge HIV CRS

    San Francisco, California, 94102, United States

  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS)

    Boston, Massachusetts, 02115-6110, United States

  • Columbia P&S CRS

    New York, New York, 10032-3732, United States

  • New York Blood Center CRS

    New York, New York, 10065, United States

  • Penn Prevention CRS

    Philadelphia, Pennsylvania, 19104, United States

  • Seattle Vaccine and Prevention CRS

    Seattle, Washington, 98104, United States

  • University of Rochester Vaccines to Prevent HIV Infection CRS

    Rochester, New York, 14642, United States

Conditions

Explore the condition pages connected to this study.